CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-8.73%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.56B
AUM Growth
+$2.56B
(-26%)
Cap. Flow
-$400M
Cap. Flow
% of AUM
-15.58%
Top 10 Holdings %
Top 10 Hldgs %
43.81%
Holding
134
New
13
Increased
7
Reduced
67
Closed
28
Top Buys
| 1 |
Monte Rosa Therapeutics
GLUE
|
$69.6M |
| 2 |
Biomea Fusion
BMEA
|
$48.4M |
| 3 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$47M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$44.6M |
| 5 |
VERV
Verve Therapeutics
VERV
|
$40.6M |
Top Sells
| 1 |
C4 Therapeutics
CCCC
|
$80.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$64.2M |
| 3 |
Novavax
NVAX
|
$45.3M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$43.6M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$32.8M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Financials | 0.16% |
